苏州工业园区康林肿瘤科技创新研究院

 

SIP LifeLink Oncology Research Institute

 

图片1

邓觅

 

>>>>

个人信息:

 

  电话:0512-62996968

  邮箱:mideng@bjmu.edu.cn

  

>>>>

教育科研经历:

 

      2000-2004        湖南师范大学,理学学士

  2004-2007        湖南师范大学,理学硕士

  2007-2012        美国内布拉斯加大学医学中心,博士

  2012-2015        美国德克萨斯大学西南医学中心,博士后 

  2015-2017        美国德克萨斯大学西南医学中心,讲师

  2017-2020        美国德克萨斯大学西南医学中心,助理教授

  2020-至今        北京大学国际癌症研究院,副研究员,博士生导师

                北京大学肿瘤医院,助理教授

                苏州工业园区康林肿瘤科技创新研究院,首席研究员

   

邓觅博士长期以肿瘤免疫学为研究方向,致力于探索肿瘤细胞逃逸免疫监控的分子机制,发现新的肿瘤免疫治疗靶点,开发大分子抗体药物、纳米抗体药物、以及细胞治疗技术。以第一作者或通讯作者在Nature、Blood、Cancer Immunology Research、Cellular and Molecular Immunology、PNAS、Antibody Therapeutics等期刊发表一系列论文,其研究结果揭示了髓系免疫检查点分子(LILRB2/ILT4)促进造血干细胞体外扩增的分子机制,阐明了髓系免疫检查点分子(LILRB4/ILT3)抑制T细胞和促进白血病细胞浸润和实现白血病细胞免疫逃逸的分子机制,以此开发了扩增造血干细胞的靶向LILRB2/ILT4受体的抗体分子、针对白血病的靶向LILRB4/ILT3受体的治疗性抗体药物、抗体/小分子药物偶联物、双特异性抗体、以及CAR-T/CAR-NK细胞治疗疗法。研究成果多次被新闻媒体美国商业咨询(Business Wire)、Yahoo、知识分子、学术专业杂志 Cancer Discovery、Blood、和Faculty 1000等推荐和报道。邓觅博士以主要发明人发表了7项美国或国际专利,其研究成果转让并成为多家美国生物科技公司的重要研发管线,包括Nohla Therapeutics Inc和Immune-Onc Therapeutics Inc。邓觅博士曾作为非临床研究项目的研究总监与Immune-Onc Therapeutics Inc合作参与针对白血病的创新性药物的研发、临床前实验、临床研究设计、和临床研究申报,并于2020年获得美国FDA临床试验批准和孤儿药资格,同年在美国9所医院开展多中心临床试验。邓觅博士长期担任国际学术期刊Translational OncologyAntibody Therapeutics杂志编委,和多本国际学术期刊审稿人。  

   
>>>>
发表论文
 

1.  Anami Y*, Deng M*, Gui X* (* Equal contribution authors), Yamaguchi A, Yamazaki C, Zhang N, Zhang CC, An Z, and Tsuchikama K. (2020) LILRB4-Targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia. Mol Cancer Ther. 19:2330-2339. (IF: 6.261)

2.  Li Z*, Deng M* (* Equal contribution authors), Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH, Zhang CC. (2020) LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 17(3):272-282. (IF: 11.53)

3.  Gui X*, Deng M* (* Equal contribution authors), Song H, Chen Y, Xie J, Li Z, He L, Huang F, Xu Y, Anami Y, Yu H, Yu C, Li L, Yuan Z, Xu X, Wang Q, Chai Y, Huang T, Shi Y, Tsuchikama K, Liao XC, Xia N, Gao GF, Zhang N, Zhang CC, An Z. (2019) Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T cell suppression and blocks AML development. Cancer Immunol Res. 7(8):1244-57. (IF: 11.151)  

4.  Deng M*, Gui X*, Kim J* (* Equal contribution authors), Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen G-Q, Fu Y-X, Liao XC, An Z, Zheng J, Zhang N, Zhang CC. (2018) LILRB4 signalling in leukaemia cells mediates T cell suppression and tumor infiltration. Nature. 562(7728):605-9. (IF: 49.962)

5.   John S*, Chen H*, Deng M* (* Equal contribution authors), Gui X, Wu G, Chen W, Li Z, Zhang N, An Z, Zhang CC. (2018) A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 26(10):2487-95. (IF: 11.454)

6.  Tang X*, Chen Z*, Deng M*, Wang L*, Nie Q*, Xiang JW, Xia Y, Yang L, Liu Y, Li DW. (2018) The sumoylation modulated tumor suppressor p53 regulates cell cycle checking genes to mediate lens differentiation. Curr Mol Med. 18(8):556-65. (IF: 2.222)

7.   Deng M*, Lu Z* (* Equal contribution authors), Zheng J, Wan X, Chen X, Hirayasu K, Sun H, Lam Y, Chen L, Wang Q, Song C, Huang N, Gao GF, Jiang Y, Arase H, Zhang CC. (2014) A motif in LILRB2 critical for ANGPTL2 binding and activation. Blood. 124(6):924-35. (IF: 22.113)

8.   Deng M*, Chen PC* (* Equal contribution authors), Liu F, Fu S, Tang H, Fu Y, Xiong Z, Hui S, Ji W, Zhang X, Zhang L, Gong L, Hu X, Hu W, Sun S, Liu J, Xiao L, Liu WB, Xiao YM, Liu SJ, Liu Y, Li DW.  (2012). The p53-Bak apoptotic signaling axis plays an essential role in regulating differentiation of the ocular lens. Curr Mol Med. 12(8): 901-16. (IF: 2.222)

9.  Liu F*, Tang XC*, Deng M*, Chen P* (* Equal contribution authors), Ji W, Zhang X, Gong L, Woodward Z, Liu J, Zhang L, Sun S, Liu J, Wu K, Wu MX, Liu XL, Yu MB, Liu Y, Li DW.  (2012). The tumor suppressor p53 regulates c-Maf and Prox-1 to control lens differentiation. Curr Mol Med. 12(8): 917-28. (IF: 2.222)

10. Liu Z*, Deng M* (* Equal contribution authors), Xiang J, Ma H, Hu W, Zhao Y, Li DW, Liang S.  (2012). A novel spider peptide toxin suppresses tumor growth through dual signaling pathways. Curr Mol Med. 12(10): 1350-60. (IF: 2.222)

11. Yan Q*, Gong L*, Deng M*, Zhang L* (* Equal contribution authors), Sun S, Liu J, Ma H-L, Yuan D, Chen P-C, Hu X-H, Liu J-P, Qin J, Xiao L, Huang X-Q, Zhang J, Li DW-C. (2010). Sumoylation activates the transcriptional activity of p32 Pax-6, an important transcription factor for eye and brain development. Proc Natl Acad Sci USA. 107(49): 21034-39. (IF: 11.205)

12. Deng M*, Chen PC* (* Equal contribution authors), Xie S, Zhao J, Gong L, Liu J, Zhang L, Sun S, Liu J, Ma H, Batra S, Li DW.  (2010). The small heal shock protein alphaA-crystallin is expressed in pancreas and acts as negative regulator of carcinogenesis. Biochim Biophys Acta - Mol Basis Dis. 1802: 621-31. (IF: 5.187)

13. Xiao L*, Gong L*, Yuan D*, Deng M*, (* Equal contribution authors), Chen L, Zhang L, Yan Q, Liu J-P, Hu X, Sun S, Liu J, Ma H, Zheng C, Fu H, Chen P, Zhao J, Xie S, Zeng X, Zou L, Xiao Y-M, Liu W-B, Zhang J, Liu Y and Li D W-C. (2010). Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death & Differ. 17(9): 1448-62. (IF: 15.828)

14. Chen H-G*, Han W-J*, Deng M*, Qin J* (* Equal contribution authors), Yuan D, Liu J-P, Xiao L, Gong L, Liang S-P, Zhang J, Liu Y, Li D W-C. (2009). Transcriptional regulation of PP-2A-Aα is mediated by multiple factors including AP-2α, CREB, ETS, and SP-1. PLoS ONE. 4(9): e7019. doi:10.1371/journal.pone.0007019. (IF: 3.24)

15.   Huang XQ, Wang J, Liu JP, Feng H, Liu WB, Yan Q, Liu Y, Sun SM, Deng M, Gong L, Liu Y, Li DW. (2005). hTERT extends proliferative lifespan and prevents oxidative stress-induced apoptosis in human lens epithelial cells. Invest Ophthalmol Vis Sci. 46(7): 2503-13. (IF: 4.799)

16.  Wang J, Feng H, Huang XQ, Xiang H, Mao YW, Liu JP, Yan Q, Liu WB, Liu Y, Deng M, Gong L, Sun S, Luo C, Liu SJ, Zhang XJ, Liu Y, Li DW. (2005). Human telomerase reverse transcriptase immortalizes bovine lens epithelial cells and suppresses differentiation through regulation of the ERK signaling pathway. J Biol Chem. 280(24): 22776-87. (IF: 5.157)

17.  Li D W-C, Liu J-P, Schmid P C, Schlosser R, Feng H, Liu W-B, Yan Q, Gong L, Sun S-M, Deng M, Liu Y. (2006). Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene. 25: 3006-22. (IF: 9.867)

18.  Yan Q, Liu WB, Qin J, Liu J, Chen HG, Huang X, Chen L, Sun S, Deng M, Gong L, Li Y, Zhang L, Liu Y, Feng H, Xiao Y, Liu Y, Li DW. (2007). Protein phosphatase-1 modulates the function of Pax-6, a transcription factor controlling brain and eye development. J Biol Chem. 282(19): 13954-65. (IF: 5.157)

19.  Qin J, Chen HG, Yan Q, Deng M, Liu J, Doerge S, Ma W, Dong Z, Li DW. (2008). Protein phosphatase-2A is a target of epigallocatechin-3-gallate and modulates p53-Bak apoptotic pathway. Cancer Res. 68(11): 4150-62. (IF: 12.701)

20.   Zhao J-Q, Xie S-S, Liu W-B, Xiao Y-M, Zeng X-M, Deng M, Gong L, Liu J-P, Chen P-C, Zhou J, Lv J-H, Yu X-Q, Wang D, Li C, Pang Y-L, Liao G-P, Liu Y, Li D W-C. (2010). Molecular cloning of the genes encoding the PR55/Bβ/δ regulatory subunits for PP-2A and analysis of their functions in regulating development of goldfish, carassius auratus. Gene Regul & Syst Biol. 4:135-48.

21.   Zhang L, Sun S, Zhou J, Liu J, Lv JH, Yu XQ, Li C, Gong L, Yan Q, Deng M, Xiao L, Ma H, Liu JP, Peng YL, Wang D, Liao GP, Zou LJ, Liu WB, Xiao YM, Li DW. (2011). Knockdown of akt1 promotes akt2 upregulation and resistance to oxidative-stress-induced apoptosis through control of multiple signaling pathways. Antioxid Redox Signal. 15(1):1-17. (IF: 8.401)

22.   Hu WF, Gong L, Cao Z, Ma H, Ji W, Deng M, Liu M, Hu XH, Chen P, Yan Q, Chen HG, Liu J, Sun S, Liu JP, Wawrousek E, Li DW.  (2012). αA- and αB-crystallins interact with caspase-3 and bax to guard mouse lens development. Curr Mol Med.12(2): 177-187. (IF: 2.222)

23.   Liu J, Ji W, Sun S, Zhang L, Chen HG, Mao Y, Liu L, Zhang X, Gong L, Deng M, Chen L, Han WJ, Chen PC, Hu WF, Hu X, Liu J, Woodward Z, Liu WB, Xiao YM, Liu SJ, Liang SP, Liu Y, Li DW. (2012). The PP2A-Aβ gene is regulated by multiple transcriptional factors including Ets-1, SP1/SP3, and RXRα/β. Curr Mol Med. 12(8): 982-94. (IF: 2.222)

24. Chen PC, Li C, Wang D, Luo ZW, Fu SJ, Li X, Li ZL, Chen XW, Li L, Huang ZX, Ji WK, Hu WF, Hu XH, Deng M, Gong L, Chen HG, Liu JP, Li DW. (2013) PP-1α and PP-1γ display antagonism and differential roles in tumorigenicity of lung cancer cells. Curr Mol Med. 13(1):220-7. (IF: 2.222)

25. Yu X, Wang Y, Deng M, Li Y, Ruhn KA, Zhang CC, Hooper LV. (2014) The basic leucine zipper transcription factor NFIL3 directs the development of a common innate lymphoid cell precursor. Elife. 3:e04406. (IF: 8.14)

26. Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, Han X, Xie F, Tyner JW, Coligan JE, Collins RH, Xiao X, You MJ, Zhang CC. (2015) The ITIM-containing receptor LAIR1 is essential for acute myeloid leukemia development. Nat Cell Biol. 17(5):665-77. (IF: 28.824)

27. Constanzo JD, Deng M, Rindhe S, Tang KJ, Zhang CC, Scaglioni PP. (2016) Pias1 is essential for erythroid and vascular development in the mouse embryo. Dev Biol. 1606(15):30300-6. (IF: 3.582)

28. Liu J, Luo Z, Zhang L, Wang L, Nie Q, Wang ZF, Huang Z, Hu X, Gong L, Arrigo AP, Tang X, Xiang JW, Liu F, Deng M, Ji W, Hu W, Zhu JY, Chen B, Bridge J, Hollingsworth MA, Gigantelli J, Nguyen QD, Li DW.  (2016). The small heal shock protein alphaA-crystallin negatively regulates pancreatic tumorigenesis. Oncotarget. doi: 10.18632/oncotarget.11668. 

29. Anami Y, Xiong W, Gui X, Deng M, Zhang CC, Zhang N, An Z, Tsuchikama K. (2017) Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. Org Biomol Chem. 15(26):5635-42. (IF: 3.876)

30. Zou Y, Luo W, Guo J, Luo Q, Deng M, Lu Z, Fang Y, Zhang CC. (2018) NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein. Eur J Immunol. 48(10):1750-63. (IF: 5.532)

31. Chen H, Chen Y, Deng M, John S, Gui X, Kansagra A, Chen W, Kim J, Lewis C, Wu G, Xie J, Zhang L, Huang R, Liu X, Arase H, Huang Y, Yu H, Luo W, Xia N, Zhang N, An Z, Zhang CC. (2020) An antagonistic anti-LILRB1 monoclonal antibody regulates anti-tumor functions of natural killer cells. J Immunother Cancer. 8:e000515. (IF: 13.751)

32. Churchill H, Fuda F, Xu J, Deng M, Zhang CC, An Z, Zhang N, Chen P, Bergstrom C, Kansagra A, Collins R, John S, Koduru P, Chen W. (2020). Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry B Clin Cytom. 100(4):476-87. (IF: 3.058)

33. Gu Z, Liu Y, Zhang Y, Cao H, Lyu J, Wang X, Wylie A, Newkirk S, Jones A, Lee M, Botten G, Deng M, Dickerson K, Zhang CC, An W, Abrams J, Xu J. (2021) Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia. Nat Genet. 53(5):672-82. (IF: 38.33)

34. Wu G, Xu Y, Schultz R, Chen H, Xie J, Deng M, Liu X, Gui X, John S, Lu Z, Arase H, Zhang N, An Z, Zhang CC. (2021) LILRB3 supports acute myeloid leukemia development and regulates T cell anti-tumor immune responses through the TRAF2-cFLIP-NF-kB signaling axis. Nat Cancer. In press.

35.  Li D W-C, Gong L, Deng M, Liu J-P, Liu M, Mao Y-W. (2010). The two lens structural proteins, αA- and αB-crystallins, prevent stress-induced apoptosis through regulation of multiple signaling transduction pathways.  In: Arrigo, Simon (eds). Small Stress Proteins and Human Diseases. Nova Science Publisher, Inc NY, USA. Chapter 1.3:27-57.

 36.   Zhang L, Yan Q, Liu J-P, Zou L-J, Liu J, Sun S-M, Deng M, Gong L, Ji W-K, Li D W-C. (2010). Apoptosis: Its functions and control in the ocular lens. Curr Mol Med. 10(9): 846-75. (IF: 2.222)

37.  Chen P, Ji W, Liu FY, Tang HZ, Fu S, Zhang X, Liu M, Gong L, Deng M, Hu WF, Hu XH, Chen XW, Li ZL, Li X, Liu J, Li DW. (2012). Alpha-crystallins and tumorigenesis. Curr Mol Med. 12(9): 1164-73. (IF: 2.222)

38.  Zhang F, Zheng J, Kang X, Deng M, Lu Z, Kim J, Zhang CC. (2015) Inhibitory leukocyte immunoglobulin-like receptors in cancer development. Sci China Life Sci, 58(12): 1216-25. (IF: 6.038)

39.  Kang X, Kim J, Deng M, John S, Chen H, Wu G, Phan H, Zhang CC. (2016) Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle, 15(1): 25-40. (IF: 3.530)

40.  Zhang H, Deng M, Lin P, Liu J, Liu C, Strohl W, Wang S, Ho M. (2018) Frontiers and opportunities: Highlights of the 2nd annual conference of the Chinese Antibody Society. Antib Ther. 1(2): 65-74.

41.  Deng M. (2019) The approval of Sinitilimab for classical Hodgkin’s lymphoma: Views and Perspectives of anti-PD-1/PD-L1 antibodies in China. Antib Ther. 2(2): 54-55.

42.  Zhang H, Deng M, Pei F, Wang S, Ho M. (2019) Next-generation antibody therapeutics: Discovery, development, and beyond: Highlights of the 3rd annual conference of the Chinese Antibody Society. Antib Ther. 2(4): 99-107.

43.  Deng M, Chen H, Liu X, Huang R, He Y, Yoo B, Xie J, John S, Zhang N, An Z, Zhang CC. (2021) Leukocyte immunoglobulin-like receptor subfamily B (LILRB): therapeutic targets in cancer. Antib Ther. 4(1): 16-33.

 

>>>>

专利

 

1.  Zhang CC, Deng M, An Z, Xiong W, Zhang N, Zheng, J. (2016) Anti-lilrb Antibodies and their use in detecting and treating cancer. (Patent number: PCT/US2016/020838)

2.  Bernstein ID, Zhang CC, Deng M, Lu Z, Zheng J. (2017) Lilrb2 and notch-mediated expansion of hematopoietic precursor cells. (Patent number: PCT/US2015/031959)

3.  Zhang CC, Liu Y, Zheng J, Deng M, Chen C, Liu J. (2017) Novel compounds supports hematopoietic stem cells and red blood cells. (Patent number: PCT/US2015/030352)

4.  Zhang CC, An Z, Zhang N, Deng M, Kim, J, Gui X. (2018) Methods for identifying lilrb-blocking antibodies. (Patent number: PCT/US2017/044171)

5.  Liao X, Liu Q, An Z, Zhang N, Gui X, Zhang CC, Deng M, Xie J. (2018) Anti-lair1 antibodies and their uses. (Patent number: PCT/US2018/012040)

6.  Zhang CC, John S, Chen H, Deng M, Gui X, Zhang N, An Z. (2019) Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer. (Patent number: PCT/US2018/059362)

7.  An Z, Zhang CC, Zhang N, Gui X, Deng M, Huang T, Liu Q, Liao X. (2020) Novel LILRB4 antibodies and uses thereof. (Patent number: PCT/US2019/050727)

 
   
 
>>>>

学术编辑工作

 

      2018-现在        Antibody Therapeutics 杂志,编委/助理编辑 

  2020-现在       Translational Oncology 杂志,编委 

 

科学研究

 

RESEARCH

 

首席研究员